-+ 0.00%
-+ 0.00%
-+ 0.00%
Impact Therapeutics says senaparib EU marketing application under EMA review, approval eyed in 2H 2026
Share
Listen to the news
Impact Therapeutics says senaparib EU marketing application under EMA review, approval eyed in 2H 2026
  • Impact Therapeutics’ senaparib ovarian-cancer maintenance filing with the EMA was accepted in August 2025; the application remains under review.
  • Approval is expected in H2 2026, positioning the drug for a potential European launch via partner Pharmanovia.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12307928), on August 31, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending